18-Apr-2024
No headlines found.
Precipio Announces Year end 2023 Shareholder Update Call
Globe Newswire (Mon, 25-Mar 5:00 PM ET)
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
Globe Newswire (Tue, 13-Feb 10:00 AM ET)
Globe Newswire (Tue, 6-Feb 10:00 AM ET)
Precipio's Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
Globe Newswire (Tue, 23-Jan 10:00 AM ET)
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
Precipio trades on the NASDAQ stock market under the symbol PRPO.
As of April 18, 2024, PRPO stock price was flat at $6.70 with 214 million shares trading.
PRPO has a market cap of $9.52 million. This is considered a Sub-Micro Cap stock.
Last quarter Precipio reported $4 million in Revenue and $.88 earnings per share. This fell short of revenue expectation by $-571,000 and exceeded earnings estimates by $1.81.
In the last 3 years, PRPO stock traded as high as $183.60 and as low as $4.75.
The top ETF exchange traded funds that PRPO belongs to (by Net Assets): VXF, VTI.
PRPO stock has underperformed the market in the last year with a return of -52.0%, while SPY returned +22.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in PRPO shares. However, PRPO has outperformed the market in the last 3 month and 2 week periods, returning +10.3% and +6.2%, while SPY returned +6.1% and -3.8%, respectively. This indicates PRPO has been having a stronger performance recently.
PRPO support price is $6.35 and resistance is $7.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRPO stock will trade within this expected range on the day.